雌莫司汀磷酸钠
雌莫司汀磷酸钠 性质
| 储存条件 | Inert atmosphere,2-8°C |
|---|---|
| 溶解度 | H2O中可溶50mg/mL |
| 形态 | 结晶固体 |
| 颜色 | 白色至米白色 |
| 水溶解性 | H2O: 50mg/mL |
| 稳定性 | 吸湿性，溶液不稳定 |
| InChIKey | ULCNDGGDDCVULG-CHZQVAATNA-N |
| SMILES | C[C@]12CC[C@]3([H])C4C=CC(OC(=O)N(CCCl)CCCl)=CC=4CC[C@@]3([H])[C@]1([H])CC[C@@H]2OP(O)(O)=O.[NaH] |&1:1,4,24,26,30,r| |
| CAS 数据库 | 52205-73-9(CAS DataBase Reference) |
雌莫司汀磷酸钠 用途与合成方法
Estramustine phosphate sodium (1 µg/mL) treatment suppressed PC3 cell growth.
Estramustine phosphate sodium (2 µg/mL) treatment significantly elevates phosphatidylserine eversion amount on PC3 cells. Estramustine phosphate sodium induces PC3 cell apoptosis.
Estramustine phosphate sodium (2 µg/mL) treatment decreases MiR-31 level. Estramustine phosphate odium induces s prostate cancer cell line PC3 apoptosis through reducing miR-31.
Estramustine phosphate sodium, a unique antitumour agent, is selectively taken up by prostate cells and exerts antineoplastic effects by interfering with microtubule of dynamics and by reducing plasma levels of testosterone.
Estrone and estradiol, products of the metabolism of Estramustine phosphate sodium, have shown antigonadotrophic activity resulting in reduced testosterone levels similar to those achieved after surgical castration.
Estramustine phosphate sodium (4-12 mg/kg; intraperitoneal injection; daily; for 2 weeks) inhibits PAC120 tumor growth 53% by day 35.
| Animal Model: | Swiss nu/nu (nude) male mice (5-week-old) bearing PAC120 tumors |
| Dosage: | 4 mg/kg, 12 mg/kg |
| Administration: | Intraperitoneal injection; daily; for 2 weeks |
| Result: | Suppressed the development of skin lesions and resulted in a dissociation between DTH response and antibody production. |
雌莫司汀磷酸钠 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025-12-22 | HY-13627 | 雌莫司汀磷酸钠 | 52205-73-9 | 5 mg | 290 |
| 2025-12-22 | HY-13627 | 雌莫司汀磷酸钠 | 52205-73-9 | 10mM * 1mLin Water | 360 |
